Forging new frontiers in CNS therapies
Delivering novel CNS therapies is scientifically, medically and operationally complex. At IQVIA, we have more data and insights than ever before to drive innovation forward.
With over three decades of experience across neurology, neurodegenerative diseases, psychiatry, sleep, CNS rare diseases and pain, our CNS team can help you design and deliver complex clinical trials.
Better Together: A community of brave minds
我们支持您的热情和专业知识，其中包括CNS治疗专家，数据科学家，项目负责人和分析师，他们无所畏惧地努力改善患者的生活。
我们的CNS团队拥有广泛的背景和专业，我们以单一的重点统一：提供创新的临床试验解决方案，将新疗法推向市场。
Complex CNS challenges
作为未满足需求的最高领域之一，中枢神经系统疾病是多种多样的，在每个生命阶段都有不同的严重程度。随着早期试验的较少和较高的流失率，CNS临床研究提出了更高的风险水平。
Foremost is the risk of an inconclusive trial result.
Given the high degree of complexity associated with the diagnosis and measurement of change in neuropsychiatric disorders, it is important to have a development partner with scientific expertise, operational resources and vast data assets to help you reach the right patients for the trial.
Global variability in data collection and reporting add further challenges to CNS clinical research. The need to collect and synthesize this data is pivotal to your trial’s success.
Overcome obstacles with the IQVIA CORE™
Our dedicated team of brave minds will help you manage risk and find the right path to success by harnessing the power of the IQVIA CORE™. This holistic approach integrates our domain expertise, unparalleled data, advanced analytics and fit- for-purpose machine learning to produce innovative approaches that get your medicines to patients faster.
The IQVIA CORE enables our experts to consistently deliver excellence via
- 数据驱动的模型to increase diversity and reliability of patient populations
- Global site capabilities including emerging markets toidentify site capacity requirements to meet trial endpoints
- Decentralized and hybrid trial solutions to直接对患者进行试验
- Focus on innovative细胞和基因疗法
- Device and wearablescapabilities to improve objectivity of outcome measurements
- Development of master protocols and自适应试验to strengthen study design and ease patient burden
Access new resources for advanced therapy development, from candidate identification through market authorization.
直接向患者带来试验，以改善访问和参与度，提高质量并缩短时间表。
Build on our experience of more than 245 rare disease studies in 96 countries to fulfill your promise of hope to millions around the world.